Evidence map›Paper›PMID 36304926›Full record

ArticleFrontiers in molecular biosciences2022

Delivery of the selenoprotein thioredoxin reductase 1 to mammalian cells.

David E Wright, Tarana Siddika, Ilka U Heinemann, Patrick O'Donoghue

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in molecular biosciences, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.4field-weighted citation impact, top 41% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Biosynthesis, Engineering, and Delivery of Selenoproteins.International journal of molecular sciences · 2023
    Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

David E WrightDepartments of Biochemistry and Chemistry, The University of Western Ontario, London, ON, Canada.
Tarana SiddikaDepartments of Biochemistry and Chemistry, The University of Western Ontario, London, ON, Canada.
Ilka U HeinemannDepartments of Biochemistry and Chemistry, The University of Western Ontario, London, ON, Canada.
Patrick O'DonoghueDepartments of Biochemistry and Chemistry, The University of Western Ontario, London, ON, Canada.
Western University · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Over-expression of genetically encoded thioredoxin reductase 1 (TrxR1) TrxR1 can be toxic to cells due to the formation of a truncated version of the enzyme. We developed a new mammalian cell-based model to investigate TrxR1 activity. Fusion of the HIV-derived cell penetrating peptide (TAT) enabled efficient cellular uptake of purified TrxR1 containing 21 genetically encoded amino acids, including selenocysteine. The TAT peptide did not significantly alter the catalytic activity of TrxR1

Indexed as

cell biologycell penetrating peptideenzymologygenetic code expansionredox biologyselenocysteinethioredoxin reductasetrans-activator of transcription peptide

Identifiers

PMID36304926
PMCPMC9595596
OpenAlexW4304175419

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.